Jonathan Kitchen Myriad Genetics ( NASDAQ: MYGN ) is down ~20% in Friday trading following reports that UnitedHealth Group ( UNH ) will no longer cover the company's genetic test that helps to determine which mental health medications are likely to work with an individual patient. Notes.
Back to Health Page
